Anti-Lingo-1 antibody can promote remyelination and is clinical trial. However the problem with antibodies is that they do not readily get into the CNS so about 99.9% of that delivered will probably not get there. In the early trials they gave it intravenously wonder if there would be a better effect of intrathecal delivery so more gets in the brain.
This study uses gene therapy to deliver the therapy to block Lingo-1 and inject a genetically engineered lentiviral vector. The virus delivers something that blocks message of Lingo-1 and this blocks a non-remyelination signal.
Would you be willing to have a viral particle put into your brain?
This is a perceived problem with this type of therapy.
However it provides additional evidence that Lingo-1 blockage is useful. In MS how will an anti-Lingo, be used given every few weeks forever or as a pulse therapy. With alemtuzumab you are being introduced to an £50,000 short course of antibody.
The phase II trial will be occurring soon.